CKD-393
/ Chong Kun Dang
- LARVOL DELTA
Home
Next
Prev
1 to 13
Of
13
Go to page
1
June 09, 2023
Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393
(clinicaltrials.gov)
- P1 | N=33 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Not yet recruiting ➔ Completed
Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
November 30, 2022
Study to Evaluate the Food Effect on Pharmacokinetics Profile and Safety of CKD-393
(clinicaltrials.gov)
- P1 | N=28 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Not yet recruiting ➔ Completed
Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
June 30, 2022
A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions
(clinicaltrials.gov)
- P1 | N=31 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Recruiting ➔ Completed
Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
April 26, 2022
A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: Chong Kun Dang Pharmaceutical
New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
March 11, 2022
Study to Evaluate the Food Effect on Pharmacokinetics Profile and Safety of CKD-393
(clinicaltrials.gov)
- P1 | N=24 | Not yet recruiting | Sponsor: Chong Kun Dang Pharmaceutical
New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
November 09, 2021
A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393 in Healthy Volunteers Under Fed Conditions
(clinicaltrials.gov)
- P1; N=30; Not yet recruiting; Sponsor: Chong Kun Dang Pharmaceutical
Clinical • New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
August 02, 2021
A Study to Investigate the PK and Safety of CKD-393
(clinicaltrials.gov)
- P1; N=26; Completed; Sponsor: Chong Kun Dang Pharmaceutical; Not yet recruiting ➔ Completed
Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
April 30, 2021
Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects
(clinicaltrials.gov)
- P1; N=24; Completed; Sponsor: Chong Kun Dang Pharmaceutical; Not yet recruiting ➔ Completed
Clinical • Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
February 24, 2021
A Study to Investigate the PK and Safety of CKD-393
(clinicaltrials.gov)
- P1; N=24; Not yet recruiting; Sponsor: Chong Kun Dang Pharmaceutical
Clinical • New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
January 12, 2021
Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393
(clinicaltrials.gov)
- P1; N=26; Not yet recruiting; Sponsor: Chong Kun Dang Pharmaceutical
Clinical • New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
November 16, 2020
A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393)
(clinicaltrials.gov)
- P1; N=48; Completed; Sponsor: Chong Kun Dang Pharmaceutical; Not yet recruiting ➔ Completed
Clinical • Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
June 16, 2020
A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393)
(clinicaltrials.gov)
- P1; N=48; Not yet recruiting; Sponsor: Chong Kun Dang Pharmaceutical
Clinical • New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
February 07, 2020
Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-393 in Healthy Subjects
(clinicaltrials.gov)
- P1; N=24; Not yet recruiting; Sponsor: Chong Kun Dang Pharmaceutical
Clinical • New P1 trial
1 to 13
Of
13
Go to page
1